Back to Search
Start Over
Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy
- Source :
- Liver International. 35:2363-2369
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- Background & Aims Despite increasing reports of hepatitis B virus (HBV) reactivation in multiple myeloma (MM), HBV reactivation in patients with resolved hepatitis B [hepatitis B surface antigen (HBsAg)-negative/anti-hepatitis B core antigen antibody (anti-HBc)-positive] is still poorly characterized. The aim of this study was to clarify its frequency and risk factors. Methods A total of 230 MM patients with resolved hepatitis B were retrospectively reviewed for HBV reactivation and biochemical flare. Results During a median 2.4 years of follow-up, HBV reactivation was diagnosed in 12 patients (5.2%). The cumulative rates of HBV reactivation at 2 years and 5 years were 5% and 8% respectively. A baseline anti-HBs-negative status (P = 0.033) and high-dose therapy/autologous stem-cell transplantation [HDT/ASCT (P = 0.025)] were significant risk factors that were positively associated with HBV reactivation. In subgroup analysis of patients treated with HDT/ASCT (n = 127), a baseline anti-HBs-negative status was the only significant risk factor for HBV reactivation (hazard ratio, 4.64; 95% CI, 1.47–14.7; P = 0.009). Discussion These data show that evaluation of anti-HBc is needed for MM patients, and suggest that monitoring of HBV DNA should be considered for patients with resolved hepatitis B undergoing HDT/ASCT, especially those who are anti-HBs-negative.
- Subjects :
- Adult
Male
Hepatitis B virus
HBsAg
medicine.medical_specialty
medicine.medical_treatment
Kaplan-Meier Estimate
medicine.disease_cause
Gastroenterology
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Hepatitis B Antibodies
Multiple myeloma
Aged
Retrospective Studies
Chemotherapy
Hepatitis B Surface Antigens
Hepatology
biology
business.industry
Hazard ratio
Hematopoietic Stem Cell Transplantation
virus diseases
Middle Aged
Hepatitis B
medicine.disease
Hepatitis B Core Antigens
digestive system diseases
Transplantation
Treatment Outcome
DNA, Viral
Immunology
biology.protein
Female
Virus Activation
Antibody
Multiple Myeloma
business
Subjects
Details
- ISSN :
- 14783223
- Volume :
- 35
- Database :
- OpenAIRE
- Journal :
- Liver International
- Accession number :
- edsair.doi.dedup.....cd850e2e34328774c293cc3bfd4b1c07